Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide (T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma.
American Society of Hematology (ASH) 49th Annual Meeting and Exposition, 8 - 11 Aralık 2007, cilt.110, ss.5096, (Özet Bildiri)
- Yayın Türü: Bildiri / Özet Bildiri
- Cilt numarası: 110
- Doi Numarası: 10.1182/blood.v110.11.5096.5096
- Sayfa Sayıları: ss.5096
- Bursa Uludağ Üniversitesi Adresli: Evet